CSF1R and lung cancer: To translate the above findings into a more clinically relevant setting, we evaluated the effect of a ”clinical trial” grade CSF-1R tyrosine kinase inhibitor (TKI) (JNJ-40346527) [48, 49] on the clonogenicity of four representative lung cancer cell lines.